Shanghai will lower prices for certain veterinary services starting on Friday.
Shanghai Health Insurance Bureau and Shanghai Health Commission issued a notice on reducing prices of some veterinary services in the city. Among them, the prices of some veterinary services such as Thromboelastography Test (TEG) will be reduced to encourage institutions to strengthen management and reduce costs. The notice will be effective from this Friday, November 1st.
Wuxi bio launches the technology platform WuXia RidGS, empowering customers to develop non-antibiotic cell lines.
shanghai, October 28, 2024 / PRNewswire/ -- global leading Contract Research, Development, and Manufacturing Organization (CRDMO) company wuxi bio (WuXi Biologics, 2269.HK) announced the launch of WuXia RidGS cell line construction platform based on high-yield glutamine synthetase (GS) in Chinese hamster ovary (CHO) expression system. This platform is a research and development platform for non-antibiotic cell lines, utilizing Zinc Finger Nuclease (ZFN) technology to knock out the endogenous GS gene in CHO cells. WuXia RidGS is derived from
The first batch of pharmaceutical fund's third quarter report is released! Shareholding in US stocks reduced, while increasing holdings in Hong Kong stocks and A-shares.
The first batch of fund managers exposed in the third quarter medical investment strategy, significantly increased the proportion of innovative drugs, especially the position of Hong Kong-listed innovative drugs with greater flexibility.
HK Stocks Update: Pharmaceutical stocks continue to strengthen, AstraZeneca-B (01541) expands its gains in the afternoon. Hong Kong approval mechanism will be extended to all new drugs starting from November.
Pharmaceutical stocks continue to strengthen, as of the time of publication, Wuxi Bio-B (01541) rose 22.76%, to 7.65 Hong Kong dollars; Zai Lab (09688) rose 15.25%, to 25.7 Hong Kong dollars; Hoyo-B (02256) rose 8.82%, to 4.32 Hong Kong dollars; Tigermed (03347) rose 11.65%, to 41.2 Hong Kong dollars; Wuxi Bio (02269) rose 6.68%, to 17.56 Hong Kong dollars.
Department of Health: The "1+" approval mechanism will be expanded to all new drugs starting from November, embodying the concept of "Hong Kong, a Good Drug Harbor".
The Department of Health announced today (25th) that, in accordance with the measures announced in the Chief Executive's Policy Address for 2024, the "1+" approval mechanism will be expanded to all new drugs starting from November 1 this year, including vaccines and advanced therapy products, embodying the concept of "good medicine available in Hong Kong." Expanding the "1+" mechanism can attract more new drugs from around the world to register in Hong Kong, providing patients with more choices, strengthening the local drug regulatory capacity, promoting the development of relevant hardware and software, and talent, and further moving towards the "first-level approval." The government will innovate the system in conjunction with technological innovation to develop Hong Kong into an international medical innovation hub. According to the "Pharmacy and Poisons Ordinance".
Hong Kong stock market midday review | The three major indices collectively climbed! The technology index rose by nearly 2%; photovoltaic stocks led the gains, lithium battery stocks rose, GCL Tech surged more than 23%, and Ganfeng Lithium rose by nearly
Network technology stocks rise, Xiaomi Group-W up 3.37%, SenseTime-W up 2.52%; lithium battery stocks up across the board, Ganfeng Lithium up 10.73%, Tianqi Lithium Corporation up 10.60%; semiconductor stocks generally rise, Solomon Systech up 7.14%, Hua Hong Semi up 5.84%.